In het jaarverslag 2022 staat het volgende over Regeneron:
Regeneron Pharmaceuticals, Inc.
In April 2016, the Company entered into a license and collaboration agreement with Regeneron (the “2016 Regeneron Agreement”).
The 2016 Regeneron Agreement has two principal components: i) a product development component under which the parties will
research, develop and commercialize CRISPR/Cas-based therapeutic products primarily focused on genome editing in the liver, and ii)
a technology collaboration component, pursuant to which the Company and Regeneron will engage in research-related activities aimed
at discovering and developing novel technologies and improvements to CRISPR/Cas technology to enhance the Company’s genome
editing platform. Under this agreement, the Company also may access the Regeneron Genetics Center and proprietary mouse models to
be provided by Regeneron for a limited number of the Company’s liver programs. At the inception of the 2016 Regeneron Agreement,
Regeneron selected the first of its 10 targets, transthyretin (“ATTR”) amyloidosis, which is subject to a co-development and co-
promotion agreement between the Company and Regeneron (the “ATTR Co/Co”).
On May 30, 2020, the Company entered into (i) amendment no. 1 (the “2020 Regeneron Amendment”) to the 2016 Regeneron
Agreement, (ii) co-development and co-funding agreements for the treatment of hemophilia A and hemophilia B (the “Hemophilia
Co/Co”) agreements and (iii) a stock purchase agreement. The collaboration expansion builds upon the jointly developed targeted
transgene insertion capabilities designed to durably restore missing therapeutic protein, and to overcome the limitations of traditional
gene therapy. The collaboration was extended until April 2024, at which point Regeneron has an option to renew for an additional two
years. The 2020 Regeneron Amendment also grants Regeneron exclusive rights to develop products for five additional in vivo
CRISPR/Cas-based therapeutic liver targets and non-exclusive rights to independently develop and commercialize up to 10 ex vivo gene
edited products made using certain defined cell types.
Since December 31, 2021, there have been no material changes to the key terms of the 2016 Regeneron Agreement and the 2020
Regeneron Amendment (the “Amended Agreements”). For further information on the terms and conditions of these agreements, please
see the notes to the consolidated financial statements included in the Company’s Annual Report for the year ended December 31, 2021.
Revenue Recognition: Collaboration Revenue. Through December 31, 2022, excluding amounts allocated to Regeneron’s purchase of
the Company’s common stock, the Company recorded $145.0 million in upfront payments under the Amended Agreements and $39.5
million for research and development services, primarily under the ATTR Co/Co agreement. Through December 31, 2022, the Company
has recognized $173.1 million of collaboration revenue under all arrangements, including $24.1 million, $25.7 million and $53.0 million
of collaboration revenue in the years ended December 31, 2022, 2021 and 2020, respectively, in the consolidated statements of operations
and comprehensive loss. This includes $11.9 million, $5.9 million, and $10.7 million, respectively, primarily representing payments due
from Regeneron pursuant to the ATTR Co/Co agreement. These revenues are offset in part by contra-revenue related to the Hemophilia
F-20
Co/Co agreements amounting to $10.4 million in the year ended December 31, 2022, $2.7 million in the year ended December 31, 2021
and $0 million in the year ended December 31, 2020.
As of December 31, 2022, there was approximately $28.8 million of the aggregate transaction price of the Amended Agreements
remaining to be recognized, which the Company expects to be recognized during the research term through April 2024.
As of December 31, 2022 and 2021, the Company had accounts receivable of $3.2 million and $2.0 million, respectively, and deferred
revenue of $28.8 million and $51.4 million, respectively, related to the Amended Agreements.
Ze zullen wel meer krijgen in 2023 dan 100 miljoen. Verder benieuwd hoeveel aandelen Regeneron inmiddels heeft verworven.